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In vitro cell line and in vivo murine models have historically dominated pre-clinical cancer
research. These models can be expensive and time consuming and lead to only a small
percentage of anti-cancer drugs gaining a license for human use. Large animal models
that reflect human disease have high translational value; these can be used to overcome
current pre-clinical research limitations through the integration of drug development
techniques with surgical procedures and anesthetic protocols, along with emerging
fields such as implantable medical devices. Ovine pulmonary adenocarcinoma (OPA)
is a naturally-occurring lung cancer that is caused by the jaagsiekte sheep retrovirus.
The disease has similar histological classification and oncogenic pathway activation to
that of human lung adenocarcinomas making it a valuable model for studying human
lung cancer. Developing OPA models to include techniques used in the treatment of
human lung cancer would enhance its translational potential, making it an excellent
research tool in assessing cancer therapeutics. In this study we developed a novel
OPA model to validate the ability of miniaturized implantable O2 and pH sensors to
monitor the tumor microenvironment. Naturally-occurring pre-clinical OPA cases were
obtained through an on-farm ultrasound screening programme. Sensors were implanted
into OPA tumors of anesthetized sheep using a CT-guided trans-thoracic percutaneous
implantation procedure. This study reports the findings from 9 sheep that received sensor
implantations. Time taken from initial CT scans to the placement of a single sensor
into an OPA tumor was 45 ± 5min, with all implantations resulting in the successful
delivery of sensors into tumors. Immediate post-implantation mild pneumothoraces
occurred in 4 sheep, which was successfully managed in all cases. This is, to the best
of our knowledge, the first description of the use of naturally-occurring OPA cases as a
pre-clinical surgical model. Through the integration of techniques used in the treatment
of human lung cancer patients, including ultrasound, general anesthesia, CT and surgery
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into the OPA model, we have demonstrated its translational potential. Although our
research was tailored specifically for the implantation of sensors into lung tumors, we
believe the model could also be developed for other pre-clinical applications.
Keywords: human lung cancer, ovine pulmonary adenocarcinoma, novel translational lung cancer model,
pre-clinical research, computed tomography-guided sensor implantation
INTRODUCTION
The process of developing and validating new anti-cancer agents
typically follows a step-wise process from in vitro and in vivo
testing through to phase I, II, and III clinical trials. It has been
estimated that several hundred million dollars and up to 10 years
of research is needed to take a drug from its initial concept to
the completion of phase III trials (1). Pharmaceutical companies
may be discouraged from developing new cancer drugs, not
only due to the resources required, but also because attrition
rates for new cancer therapeutics are very high. Only 5% of
agents that show pre-clinical promise gain a license to be used
in patients after phase III trials (2). While the use of in vitro
techniques and in vivo murine models are well-established in
pre-clinical cancer research, fewer large animal translational
models have been described. These models show promise
in overcoming current limitations in pre-clinical research by
permitting the integration of drug development techniques with
surgical procedures and anesthetic protocols, along with novel
cancer therapeutic strategies such as implantable medical devices.
The use of implantable medical devices for cancer diagnosis,
treatment, and monitoring is becoming attainable due to
advances in electronics and microfabrication techniques. In vivo
murine studies have already shown that implantable devices can
be used to detect cancer secreted biomarkers (3) or to release
chemotherapy drugs directly within tumors (4). Numerous
other studies have also investigated the biocompatibility and
functionality of implantable devices using in vivo (predominantly
rodent) models for a range of other disease conditions, providing
evidence of their increasing potential for clinical uses (5).
Lung cancer remains the most commonly diagnosed cancer
in the world, with ∼1.8 million new cases and 1.6 million
cancer-related deaths recorded each year (6). Information on
the molecular basis and pathogenesis of human lung cancer
continues to grow through the use of numerous in vitro cell line
and in vivomurinemodels (7–12). However, pre-clinical research
using murine models has failed to improve overall survival rates,
which remains low (∼15%).
Comparative oncology is the use of naturally-occurring
cancers that arise in veterinary species for the study of cancer
biology and therapy (13); this approach is increasingly being used
to reconcile the gap between in vitro experiments, in vivo small
animal research and human clinical trials. Naturally-occurring
tumors within veterinary species that have incidence rates or
pathological similarities comparable to human cancers have
considerable potential as translational models of human disease
(14). Ovine pulmonary adenocarcinoma (OPA) is a naturally-
occurring neoplastic lung disease caused by the jaagsiekte sheep
retrovirus (JSRV) (15–18). The disease is regarded as a valuable
translational pre-clinical research model for studying human
lung cancer, overcoming many of the limitations associated with
current murine models (19).
The Implantable Microsystems for Personalized Anti-Cancer
Therapy (IMPACT) programme (University of Edinburgh)
is developing miniaturized implantable O2 and pH sensors
designed to monitor the tissue microenvironment within a solid
tumor. The identification of hypoxic tumor regions should
improve the ability to target these radiation and chemo-resistant
areas (20). Each sensor is fabricated on a silicon chip and bonded
to a 1.7 × 200mm long flexible printed circuit board lead. The
sensors are sealed in biocompatible epoxy resin, resulting in an
overall sensor size of ∼2.8 × 5.1 × 1.4mm (width × length
× height). The sensors are sterilized using ethylene oxide. We
have capitalized upon a naturally-occurring OPA model in order
to validate these sensors within a solid tumor. By integrating
techniques used in the treatment of human lung cancer patients
(ultrasound, general anesthesia, CT, and surgery) into the OPA
model, we have shown its translational potential. Whilst our
model was specifically developed for the implantation of sensors
into solid tumors, we believe it has considerable potential for
other pre-clinical studies.
MATERIALS AND METHODS
Studies were undertaken under a UK Home Office Project
License in accordance with the Animals (Scientific Procedures)
Act 1986 and with approval from the University of Edinburgh
Animal Welfare and Ethical Review Boards. The recommended
guidelines for welfare and use of animals in research were
followed. Nine adult female sheep (Highlander, n = 1; Scottish
blackface, n = 7; Scotch Mule, n = 1), weighing 39–65 kg
and diagnosed with naturally-occurring pre-clinical OPA, were
obtained through an on-farm ultrasound eradication programme
(21, 22). Sheep were bedded on straw, with ad libitum access to
food and water in groups of at least 2 animals and were allowed a
period of adaptation of at least 24 h before undergoing anesthesia.
General Anesthesia
Anesthesia was managed by specialist veterinary anesthetists
or by veterinary surgeons enrolled in a specialist training
programme under supervision. All sheep underwent
preanaesthetic assessment, which involved distant observation
of demeanor, breathing rate and pattern, and was followed
by physical examination. Only animals that were judged fit
for anesthesia were subsequently studied. Food was withheld
for 12 h before anesthesia, but access to water was permitted
until preanaesthetic medication was administered. Anesthesia
and analgesia techniques are provided in Table 1. Intravenous
preanaesthetic medication was administered to reduce animal
stress, facilitate the induction of anesthesia and to decrease
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TABLE 1 | Techniques used to provide anesthesia and analgesia in sheep with ovine pulmonary adenocarcinoma in pre-clinical research.
Phase Drug Manufacturer Dose (mg/kg) Route
Sedation Medetomidine
in combination with
“Sedator”; Dechra Veterinary Products, Shrewsbury, UK 0.003–0.01 i.v.
Midazolam “Hypnovel”; Roche, Welwyn Garden City, UK 0.25–0.5 i.v.
Induction Propofol “Propofol”; Fresenius Kabi, Cheshire, UK To effect* (e.g., 3–10) i.v.
Maintenance Isoflurane “IsoFlo”; Abbot Animal Health, Maidenhead, UK inhaled
Analgesia Flunixin “Flunixin Injection”; Norbrook, Newry, UK 2.2 i.v.
Morphine “Morphine Sulfate”; Martindale Pharmaceuticals, Essex, UK 0.1–0.3 i.v./i.m.
*Until conditions for endotracheal intubation are present. (i.m., intramuscular; i.v., intravenous).
induction agent dose requirements. General anesthesia was
induced within 10min of preanaesthetic medication to minimize
sedation-induced respiratory depression. Before this, and when
necessary, the head was elevated to prevent respiratory secretions
and rumen contents entering the upper airway. After induction of
anesthesia, the trachea was intubated with a cuffed endotracheal
tube and the cuff inflated. Anesthesia was maintained using
isoflurane (Abbot Animal Health, Maidenhead, UK) vaporized
in an O2/air mixture, administered using a Bain or circle
breathing system connected to the endotracheal tube. End-tidal
concentrations of 1.5–2.0% isoflurane were used to ensure
unresponsiveness to subsequent procedures. Oropharyngeal and
tracheobronchial suction was performed to remove respiratory
secretions when required. After tracheal intubation, the lungs
were ventilated mechanically to achieve tidal volumes of 8–10
ml/kg. Respiratory rate was adjusted to maintain normocapnia
(PaCO2 range 4.7–6 kPa). Body temperature was monitored
using rectal and esophageal thermistors and maintained between
38.5◦C and 39.5◦C. A central (jugular) venous 14G cannula was
used for administering drugs and crystalloid fluids. Compound
sodium lactate (Aqupharm No 11, Animalcare, York, UK) was
infused at 5/ml/kg/h in order to sustain cardiac preload and
replace lost fluids and electrolytes. Mean arterial blood pressure
was maintained between 70 and 80 mmHg and monitored
using an arterial cannula placed in the central auricular artery.
Blood samples obtained from the arterial cannula was used
for intermittent blood-gas, biochemical and hematological
analysis (Epoc portable blood gas electrolyte and critical care
analyser; Woodley Equipment Company Ltd, Lancashire,
UK). A multiparameter patient monitoring device (Datex-
Ohmeda S/5, SOMA Technology, Madison, USA) was used
to continuously monitor pulse rate and blood pressure along
with pulse oximetry, capnography, temperature, spirometry,
electrocardiography and inspired and expired gases (O2, CO2,
and inhalant anesthetic agent) (Figure 1). Analgesic agents were
administered pre-emptively either at the time of sedation or
immediately post-induction. All animals were euthanized with
intravenous sodium pentobarbitone (Pentoject; Animalcare,
York, UK).
Computed Tomography Imaging
A single-section SOMATOM Definition AS 64 slice helical CT
machine (Siemens Healthcare Ltd, Camberley, UK) was used for
all advanced imaging procedures. The imaging parameters of the
scanner were 120 kVp, 35mA, 3–5mm collimation with 1mm
section thickness. The window width and level were ∼2,000 and
−500 HU, respectively, allowing simultaneous visualization of
the needle tip, blood vessels, OPA lesions, pneumothorax, bone,
muscle, and fat. All scans were performed to include the entire
thoracic cavity from the thoracic inlet to the last rib.
Development of a Trans-Thoracic
Percutaneous Technique for Sensor
Implantation Into OPA Tumors
The model was initially developed using cadavers of OPA-
affected sheep; simulated surgeries were performed on 8 sheep
cadavers with multiple sensor implantations in each carcass.
These surgeries allowed the development of the implantation
procedure and investigation of the potential accessible regions
of the thoracic cavity and lung lobes into which sensors could
be safely implanted. To refine the surgical procedure further, 3
sheep diagnosed with pre-clinical OPA by ultrasound screening
underwent anesthesia and sensor implantation as developed from
the cadaveric studies. Refinements to the procedure included
the use of radiopaque grid lines for improved accuracy of
lesion localization and performing serial CT scans to aid needle
positioning and sensor implantation. These staged series of
experiments allowed the development of our OPA model; each
development stage increased the complexity of the model,
resulting in the refined protocol used in experimental cases.
All experiments were conducted on anesthetized animals.
After induction of anesthesia, sheep were placed in lateral
recumbency with the diseased lung uppermost. The thorax was
clipped between the caudal border of the last rib and the caudal
border of the scapula. The dorsal margin extended from the
dorsal spinous process of the thoracic vertebrae ventrally to the
sternum. An initial CT scan was taken to assess intra-thoracic
pathology and identify OPA lesions for implantation. Lesions
were selected so the needle path would avoid bullae, fissures,
visible blood vessels, and large bronchioles. Peripheral lung lobe
lesions of at least 4 cm diameter were preferred to limit the
volume of normal aerated lung that the needle would pass
through and to improve sensor implantation into OPA tissue
(Figure 2). To aid OPA lesion localization and determine the
site for percutaneous sensor placement, initial CT scans were
performed with a self-adhesive sheet of non-metallic, radiopaque
grid lines (GuideLines, Oncology Imaging Systems, UK) placed
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FIGURE 1 | Photographs of imaging and surgical facilities. (a) The sheep is anesthetized and positioned for CT scanning in lateral recumbency, with the OPA affected
lungs uppermost. The anesthetic monitoring equipment can be seen to the left-hand side of the image. (b) For sensor implantation a general surgical kit is required
along with the Jamshidi insertion needle. An IMPACT sensor can be seen in a bottle of sterile saline at the top right-hand side of the image. (c) Macroscopic image of
the IMPACT O2 sensor encapsulated in a biocompatible epoxy resin and bonded to the lead wire.
on the thoracic wall skin surface. OPA lesions were localized
dorso-ventrally based on the grid lines and cranio-caudally based
on intercostal spaces. The distance between the skin and pleura
was measured at the anticipated penetration site. A mark was
drawn on the skin surface to identify the position of thoracic
wall penetration for sensor implantation. The grid lines were
removed, and the skin was aseptically prepared for surgery using
chlorohexidine solution, after which the area was four quarter
draped for surgery (Figure 3).
All sensors were inserted using a trans-thoracic percutaneous
technique under CT guidance. Based on the initial pre-operative
CT scan a 1 cm vertical skin incision was made ∼1–2 intercostal
spaces caudal to the desired entry point into the thoracic
cavity. An 8G × 15 cm Jamshidi biopsy needle (Carefusion,
France), with its stylet in place, was advanced cranially through
subcutaneous tissues, then redirected perpendicular to the
thoracic wall in the center of the chosen intercostal space. The
needle was advanced through the chest wall (based on the pre-
measured distance from the initial CT scan), with the penetration
of the parietal pleura appreciated as the feeling of a “pop.” The
needle, at this point, was within the thoracic cavity through the
parietal pleura, but not penetrating lung/OPA tissue. A second
CT scan at this stage confirmed the position of the needle. If
necessary, the needle could be repositioned with minimal risk of
lung damage as the needle had not penetrated the visceral pleura.
Once in the correct position the needle was slowly advanced
through the visceral pleura into OPA tissue; repeat CT scans were
taken following each needle advancement and measurements
were made determining the distance from needle tip to the
point of desired sensor implantation. Following placement of the
needle tip centrally within OPA tissue, the stylet was removed
from the Jamshidi needle and the sensor and lead wire were
introduced down the bore of the needle. The obturator was
then placed down the bore of the needle, advancing the sensor
past the tip of the needle into OPA tissue. Once in place, the
obturator and implantation needle were withdrawn, leaving the
sensor and lead wire in situ. A purse string suture of 3 metric
braided silk (Mersilk, Ethicon UK), placed around the incision
which continued as a Chinese finger trap suture around the lead
wire, secured the sensor in place (Figures 4, 5). Final CT scans
were performed to evaluate sensor positioning and assess any
immediate post-operative complications such as pneumothorax
or hemorrhage. The decision to drain any pneumothorax that
developed (though percutaneous thoracocentesis) was made
based on its severity. Post-mortem examination was performed
following the completion of the experiments to assess the extent
of lung pathology, identify the implant site and to obtain biopsy
specimens for histopathology.
Histopathology
OPA tissue was fixed for at least 24 h (depending on tissue
thickness) in 4% formaldehyde (Genta Medical, UK) before
undergoing processing using the Thermo Scientific Excelsior AS
Tissue Processor (Thermo Scientific, UK) and embedding in
paraffin. Tissue was sectioned using the Leica RM2235 rotary
microtome (Leica Microsystems Ltd, UK); microtome sections
of 4µm were placed on SuperFrost Plus glass slides (Thermo
Scientific, UK) and allowed to dry for a minimum of 4 h at 53◦C.
For haematoxylin and eosin staining, sections were
deparaffinised by 3 changes in 100% xylene for 5min, then
rehydrated by placing into alcohol; 2 changes in 100% ethanol,
followed by 80% then 50% for 2min each time. The slides
were washed in running water for 2min, before placing
in haematoxylin (Shandon Harris Haematoxylin, Thermo
Scientific, UK) for a maximum of 10min. Slides were washed in
running water for 2min and then placed into Scott’s tap water
substitute for a maximum of 10min until the tissue sections
turned blue. Sections were counterstained by placing them into
Eosin Y (Shandon Eosin Y Cytoplasmic Counterstain, Thermo
Scientific, UK) for 5min. The slides were dehydrated by placing
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FIGURE 2 | Initial CT images are used to assess intra-thoracic pathology. (a) Axial, (b) Coronal, and (c) Sagittal planes. A large area of increased radiopacity,
consistent with an OPA lesion, can be seen affecting the ventral regions of the left cranial and caudal lung lobes (outlined in black). Air bronchograms are visible within
this region (white arrows). An area of patchy and hazy increased opacity (ground glass appearance) within the dorsal regions of the lung, with preservation of bronchial
and vascular patterns, can also be identified (outlined in white); this increased opacity may due to the presence of diffuse areas of neoplastic foci or pneumonia. The
radiopaque circles on the skin surface seen on the axial plane are the grid lines used for OPA lesion localization.
FIGURE 3 | OPA lesion localization. The hemithorax has been clipped for surgery and the radiopaque grid lines are placed on the skin surface. (a) The grid lines are
placed on the skin surface prior to the initial CT scan. (b,c) The skin is marked both dorso-ventrally and cranio-caudally at the desired implantation point based on the
initial CT images.
them into alcohol; 50% ethanol for 30 s, 80% ethanol for 30 s,
then 2 changes in 100% ethanol for 2min. The slides were placed
in xylene for 10min before being mounted with coverslips using
DXP mountant (Sigma-Aldrich, UK).
Assessment of Radiation Exposure During
CT-Guided Sensor Implantations
To assess the amount of radiation that sheep were exposed to
during CT-guided sensor implantations, the total number of CT
imaging events (topograms or full thoracic scans) were recorded
and individual imaging event and total dose length products
(DLP) were calculated for each sheep. Individual event DLP is
calculated from the CT dose index volume (CTDIvol), which is
in turn based on the radiation received inside a phantom from a
single rotation of the scanner, this value is then multiplied by the
scan length. Total DLP for each sheep was calculated from the
sum of all individual DLP’s. DLP is proportional to the effective
dose received by a patient and is used, in combination with CTDI,
to compare scanning protocols and establish diagnostic reference
levels (23).
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FIGURE 4 | Intra-operative photographs depicting trans-thoracic percutaneous sensor placement. (a,b) A skin incision is made through which the Jamshidi needle is
introduced. (c–e) Following successive CT scans the needle is progressively advanced into OPA tissue. (f–h) Once the needle is in position the stylet is removed and
the sensor introduced down the bore of the needle. (i) The obturator is used to push the sensor past the tip of the needle into OPA tissue. (j–l) The Jamshidi needle is
removed, leaving the sensor and lead wire in place. (m–o) The skin is closed, and lead wire secured in place with a purse string and Chinese finger trap suture.
Statistical Analysis
Data for blood-gas, biochemical and hematological analysis was
analyzed with parametric tests. One-way ANOVA with Holm-
Šídák multiple comparisons test were used to test for differences
over time; p-values <0.05 were deemed statistically significant.
Data are shown as mean ± SEM, with all statistical analysis and
graphs generated using Prism 7 (GraphPad Software, San Diego,
CA, USA).
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FIGURE 5 | Serial CT images taken during sensor implantation. Coronal, axial, and sagittal planes are viewed following initial needle placement and after each needle
advancement. The Jamshidi needle (yellow arrows) is advanced until the tip is positioned at the desired point within the OPA lesion. CT images taken immediately
post-implantation demonstrates sensor placement within OPA tissue in all 3 planes (red arrows).
RESULTS
Appropriate Anesthetic Protocols Enable
OPA Sheep to Remain Physiologically
Stable Throughout Anesthesia
To assess the physiological stability of OPA-affected sheep
throughout anesthesia, data from blood-gas, biochemical, and
hematological analysis was combined with variables such as
heart rate, respiratory rate, body temperature, and mean
arterial blood pressure. Results from sheep maintained with
an inspired fraction of O2 (FIO2) of 1.0 are shown in
Figure 6 (n = 3–5 per time point). The remaining 4 cases
in this study were subjected to alterations in FIO2 for sensor
validation experiments and are therefore not included in this
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analysis. Results showed that physiological and arterial blood
variables remained stable throughout anesthesia. No statistically
significant changes over time were identified in any measured
variable (Figure 6).
Elevated blood lactate persisted throughout anesthesia but
showed a tendency to reduce at later time points (Figure 6A).
Blood pH, base excess and bicarbonate showed a similar, but
opposite response (Figures 6F,G). Arterial O2 partial pressure
(PaO2) showed marked individual variation (Figure 6B) and
was consistently lower than expected given the FIO2 of 1.0,
suggesting a compromise in the degree of O2 uptake by the
alveoli. Despite this, it was possible to maintain a hemoglobin
O2 saturation (SaO2) of ≥ 95% (Figure 6C). Peak inspiratory
pressure increased throughout anesthesia (Figure 6D), with
mean peak inspiratory pressures at 180min almost 1.5 times
greater than that recorded at 30min. Airway suction was
frequently required to clear respiratory secretions. To support
mean arterial blood pressure (Figure 6E), 3 sheep required
management with intravenous fluids or vasopressors. Additional
treatments administered during anesthesia included atropine
(1 sheep; severe bradycardia), sodium bicarbonate (1 sheep;
acidosis), and glucose (1 sheep; hypoglycaemia).
CT-Guided Trans-thoracic Percutaneous
Sensor Implantation Resulted in a High
Success Rate of Delivery of Sensors Into
OPA Lesions
A total of 9 sheep underwent general anesthesia and sensor
implantation (2 additional cases were excluded from analysis due
to a lack of histological evidence of OPA following post-mortem
examination). Of the 9 OPA-affected sheep that underwent
CT-guided sensor implantations into tumor tissue, 7 cases
received a single sensor implantation and 2 cases received 2
sensors implanted into a single large OPA lesion. In the case
of single sensor implantations, time taken from the initial CT
scan to sensor placement was 45 ± 5min (mean ± SEM).
Double implantations took a little longer, with implant times
of 50 and 73min for each case. The number of sequential
CT scans and needle advancements required from the initial
needle placement to obtaining the desired position within OPA
tissue ranged from 3 to 5, with 4 advancements required in
9 of the 11 sensor implantations. All implantation procedures
resulted in sensor placement within OPA tissue (Figure 7).
No immediate complications were identified in 5 of the cases
(Table 2). Estimates of the amount of radiation received by
each sheep undergoing CT-guided sensor implantation were
calculated. DLPs for individual topograms and full thoracic scans
were 9± 0.3 mGy cm and 392± 11 mGy cm, respectively (mean
± SEM), whereas total DLP for each sheep was 2,856± 392 mGy
cm (mean± SEM).
Iatrogenic Pneumothorax Is a Potential
Complication Following Percutaneous
Sensor Implantation
Sensor implantation in 4 cases immediately resulted in mild
pneumothoraces; however, only 2 of these cases required
treatment with percutaneous thoracocentesis. CT scans
post-thoracocentesis confirmed lung lobe re-expansion and
removal of most of the air from within the thoracic cavity.
Sensor positioning was not affected by the occurrence of a
pneumothorax and the sensor remained within the OPA lesion
post-thoracocentesis (Figure 8).
All Implantation Sites Were Identified
During Post-mortem Examination
All sheep underwent post-mortem examination following
euthanasia. Gross pathology allowed assessment of lung
pathology, identification of the implant site, and provided the
opportunity to obtain biopsy specimens for histological analysis.
Gross pathology identified lesions that were in accordance with
those identified on the CT scans in terms of number of lesions,
location, and size. All sensor implantation sites were successfully
identified with an entry site seen in the visceral pleura directly
overlying OPA tissue. In 1 case an area of petechial hemorrhage
was evident to the lung surface in the region of the implantation
site; however, the remaining cases had no gross evidence of
parenchymal hemorrhage or haemothorax (Figure 9). Following
examination of gross pathology, the implant site was dissected
from the OPA tissue. The biopsy specimen was used for both
OPA diagnosis and to assess the effects of the implantation
procedure on OPA/lung tissue. Histological examination
confirmed OPA diagnosis in all 9 cases (the 2 excluded cases were
reported as lung consolidation with marked pleural fibrosis and
pleuritis). Evidence of hemorrhage within the needle tract and
erythrocytes present within tumor tissue immediately adjacent
to the implant site were identified in all cases (Figure 10).
DISCUSSION
Similarities between OPA and human lung adenocarcinomas
in terms of disease presentation, progression, and histological
classification has led to the recognition of OPA as an excellent
model for studying human lung cancer biology (24). In vitro
(25–29) and in vivo (30–35) OPA experimental models are
well-documented and have been successfully used to identify
molecular pathways involved in lung cancer pathogenesis.
However, for OPA to be used as a translational pre-clinical
research model for human lung cancer, techniques used in the
diagnosis and treatment of human patients must be incorporated
into the model. In order to achieve this aim, protocols currently
used in human thoracic medicine were incorporated into our
novel OPA model, which was used for validation of the sensors
which have been developed as part of this project (20).
Although certain thoracic procedures in human medicine are
commonly performed under local anesthesia, general anesthesia
was mandatory in our OPA model to ensure animal and
personnel safety. It is therefore important to consider the
general anesthetic requirements of these sheep if they are to be
used in translational research. General anesthesia of sheep with
OPA can be challenging but is entirely feasible if facilities and
expertise are in place to provide, if required, respiratory, and
cardiovascular support. These animals have variable amounts
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FIGURE 6 | (A–J) Physiological parameters and arterial blood biochemical and hematological analysis. Physiological data obtained from OPA cases maintained at
FIO2 of 1.0 throughout anesthesia (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n = 3–5 per time point; times
indicate min post-induction of anesthesia) (PaO2, arterial O2 partial pressure; PaCO2, arterial CO2 partial pressure; SaO2, hemoglobin O2 saturation; Hb, hemoglobin;
PIP, peak inspiratory pressure; RR, respiratory rate; MAP, Mean arterial blood pressure; HR, heart rate; ABE, arterial base excess; HCO−3 , bicarbonate; CT, core
temperature).
of respiratory compromise resulting from the OPA lesion(s),
lung lobe consolidation, increased respiratory tract secretions,
secondary infections, and anesthesia-induced atelectasis. All
these factors will hinder the effective movement of inspired
O2 into the blood, leading to lower PaO2 levels. Adequate
blood O2 content in our cases was maintained by increasing
the inspired fraction of O2 in combination with mechanical
ventilation. The use of elevated peak inspiratory pressures in our
cases was well-tolerated and was necessary to achieve adequate
ventilation due to reduced compliance of the diseased lungs.
The sheep in our study also had elevated blood lactate levels,
which could have been caused by global tissue hypoxia; however,
as neoplasia itself can elevate blood lactate levels (36) it is
difficult to know its specific underlying etiology. The decrease
in lactate levels that occurred throughout anesthesia may have
been due to the provision of intravenous fluid therapy and
mechanical ventilation which contribute to improved tissue
O2 delivery. Although we have shown that OPA cases may
require additional anesthetic monitoring with respiratory and
cardiovascular support, all our cases were successfully managed
throughout sensor validation experiments. These results provide
evidence that OPA cases, even with relatively large tumors
(as was seen with a number of our cases), can be used in
procedures that require general anesthesia. Although, it should
be noted that these were pre-clinical OPA cases identified by
ultrasound screening and sheep showing clinical signs of OPA
were specifically excluded from the study.
Lung cancer diagnosis in human patients is performed
through immunohistochemistry using aspirates or biopsy
samples taken using a flexible bronchoscope (37), or via a
minimally-invasive trans-thoracic approach (38–40). The choice
of which technique to use is dependent on the location of
the lesion. Central lesions involving a bronchus will be readily
assessible with a bronchoscope, whereas peripheral lesions that
are either not visible on endobronchial examination (41), <3 cm
in diameter or those that do not show a bronchus entering
the lesion on CT images will be more suited to minimally
invasive trans-thoracic needle biopsy (TTNB) (38, 39, 42).
Both endoscopic and percutaneous biopsy techniques could
have been modified for use in our OPA model; however, for
several reasons the trans-thoracic percutaneous approach was
chosen. Naturally-occurring JSRV infection and transformation
will typically result in OPA lesions forming initially at peripheral
lung lobe regions. It is only as neoplastic foci enlarge and
coalesce that central lobe regions become affected. Although
tumor tissue will frequently involve bronchioles, larger bronchi
may remain largely unaffected. Although endoscopy can be
routinely performed in sheep (43), successful endoscopic sensor
implantation would only be possible in tumors which involved
bronchi of sufficient diameter that could accommodate an
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FIGURE 7 | CT images taken immediately post-sensor implantation. Images (a–c) are from 3 separate OPA cases. The sensor and lead wire (red arrows) can be seen
within the area of increased radiopacity, consistent with a large OPA tumor.
endoscope. This specific set of selection criteria would limit
the number of cases that could be used, and logistically
could only be assessed once a sheep is anesthetized and
CT images have been obtained. As OPA tumors can be
associated with significant volumes of lung fluid production,
present in the large and small airways, this would hamper
endoscopic airway visualization and make sensor implantation
extremely challenging. The sensor for which we developed the
model is currently wired therefore endoscopic implantation
would require the lead wire to run up through the large
airways and out through the larynx to be connected to
external instrumentation; the presence of the endotracheal
tube would make this almost impossible. These limitations
associated with endoscopic sensor delivery led us to develop
the minimally invasive trans-thoracic percutaneous approach for
sensor implantation.
In humanmedicine TTNB requires the use of image guidance.
Fluoroscopy, once the preferred imaging choice, enables needle
advancements to be visualized in real-time (44); however, the
technique has become less popular as it is not compatible
with accessing deep lesions and the avoidance of vascular
structures and bullae (45). Image guidance using ultrasound
enables needle movements to be monitored precisely and quickly
during the TTNB (46, 47); however, its use is restricted to
peripheral lesions that produce an acoustic window. CT is
currently the most commonly used image guidance technique
for TTNB (48–50). Unlike fluoroscopy, CT allows accurate
planning of needle path trajectories that avoid aerated lung,
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TABLE 2 | Details of OPA cases used and implantation results.
Case Signalment Weight
(kg)









65 Left caudal lobe: 1 focal lesion
at cranial aspect of caudal lobe,
∼4–5 cm diameter





51 Right caudal lobe: 1 diffuse area
at caudal aspect ∼4–5 cm
diameter
3 58 Mild pneumothorax: treated

















57 Right cranial lobe: Almost entire
lobe affected
4 26 None
Left caudal lobe: 1 Focal lesion





39 Left cranial lobe: Entire lobe
affected





55 Right cranial lobe: Entire lobe
affected
5 43 None
Left cranial lobe: Entire lobe
affected, extending into the





58 Right accessory lobe: Entire
lobe affected
4 73 None
Left cranial lobe: Entire lobe
affected, extending into the





64 Right cranial lobe: Almost entire
lobe affected
4 50 Mild pneumothorax: treated
successfully with a single
thoracocentesis
Cases 1–7 had single sensor implantations, whereas cases 8 and 9 had 2 sensors implanted. Signalment, CT localization, time from initial CT scan to sensor implantation, number of
CT scans/needle advancements required, and immediate post-implantation complications are provided.
bullae, fissures, and blood vessels. The procedure can also be
used to sample central lesions, lesions <1 cm in diameter (51)
and, similar to ultrasound, can distinguish between necrotic and
solid regions of a lesion, allowing for more accurate needle
positioning and better diagnostic samples to be obtained. CT
can be combined with fluoroscopy (CTF) to allow needle
adjustments to be made in almost real-time. The technique
is primarily used for very small lesions located in difficult to
access thoracic regions (costodiaphragmatic recess, near to the
mediastinum or critical at-risk structures) and can be performed
quickly, which is advantageous in un-cooperative or high-risk
patients (52). Although any of these image techniques can be
integrated for use within the OPA model, CT was chosen in
our study for several reasons. CTF was not considered necessary
as sheep were selected for use in our experiments on the
basis that they had reasonably large OPA lesions in relatively
accessible lung regions. CTF would also have required the
use of lead aprons and radiation shields for safety purposes.
Although ultrasound guidance could have been used for sensor
implantations into OPA lesions affecting pleural surfaces, the
technique could not provide an assessment of pathological
lesions occurring throughout the entire thorax, and thus cannot
be used to aid the selection of the most appropriate lesion for
implantation. These factors directed us to use CT guidance for
sensor implantations.
Serial CT scans were performed during the implantation
procedure, with each CT scan reviewed at each stage of the
process. The initial CT scan was used to select the OPA lesion
to undergo sensor implantation, while sequential scans were
used to assess needle trajectory and position. Lesion selection
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FIGURE 8 | CT images documenting iatrogenic pneumothorax. The OPA target lesion is seen as a patchy area of increased radiopacity affecting the ventral region of
the left caudal lung lobe. CT scans were taken immediately post-sensor implantation and following thoracocentesis. A mild pneumothorax (outlined in blue) was
evident immediately post-sensor implantation, predominately localized to the region of the implantation site. The sensor can be seen within OPA tissue (red arrows).
Thoracocentesis was performed immediately post-sensor placement, which resulted in lung lobe re-expansion and removal of most of the air from within the thoracic
cavity; however, a small pneumothorax at the dorsal aspect of the thoracic cavity was still evident (outlined in blue).
and needle path planning was based on known risk factors
associated with the development of TTNB complications in
human patients, predominantly pneumothorax and hemorrhage.
Small lesions and the presence of emphysema (53) or chronic
obstructive pulmonary disease (54) can increase complication
rates. Although it is possible that these diseases can occur with
OPA, we did not see any evidence of them based on CT imaging;
therefore, their association with complications seen in the OPA
model is likely to be low. Technical factors associated with
performing TTNB are also known to influence the occurrence
of post-operative complications, these factors are likely to have
played a more significant role in the complication rate seen in
our model. Technical factors that can increase the risk of TTNB
complications include increased amounts of normal aerated lung
crossed by the needle (55, 56), a small oblique needle angle
with the thoracic pleura (57), repositioning the needle multiple
times (58), a greater number of sampling procedures (59), the
absence of previous ipsilateral surgery (60), using a trans-fissure
approach (56) and damage to thoracic vasculature. In accordance
with these known risk factors, lesions were chosen so that the
needle path avoided passing through bullae, large blood vessels,
bronchi and interlobar fissures. If more than one lesion was
present, a peripheral lesion was chosen to decrease the amount
of lung tissue that would be traversed (61). It is interesting to
note that procedural length or needle dwell time within the lung
is not associated with increased risk of pneumothorax (59). In our
model single sensor implantations were performed in a time of 45
± 5min (mean± SEM), similar to studies in human patients that
document CT-guided TTNB times of up to 66 min (59).
In human medicine, monitoring and standardization of
radiation dose from diagnostic and interventional procedures is
now commonly performed in an effort to minimize potential
risks to patients from radiation exposure (23). In our model the
mean DLP for a single full thoracic scan was 392 ± 11 mGy
cm (mean ± SEM), which is comparable with recommended
diagnostic reference levels of 517 mGy cm used for human
thoracic CT scans (62). As previously described, multiple
CT scans were performed during sensor implantations, which
resulted in a total mean DLP of 2,865 ± 392 mGy cm (mean
± SEM). This value is higher than that reported in the human
literature for patients undergoing CT-guided TTNB, with one
study documenting a total mean DLP of 801 mGy cm (63).
However, in the same study DLPs as high as 3,684 mGy cm were
reported for patients undergoing thoracic drainage procedures.
The relatively high total DLPs observed in our study was due
to the need to obtain high quality images for accurate needle
path planning and sensor placement, which in combination with
additional post-sensor implantation scans, will have increased
the total radiation dose received by each sheep. However, as our
results have shown that single thoracic scans were lower than
human recommended diagnostic reference levels and reports for
patients undergoing thoracic drainage, this provides evidence
that CT-guided techniques in sheep are comparable with similar
human procedures.
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FIGURE 9 | Photographs depicting gross pathology seen in typical OPA cases. Each implantation site is highlighted with a black arrow. (a) Large gray consolidated
mass affecting the majority of the left caudal lung lobe. An area of petechial hemorrhage can be seen on the surface of the lung surrounding the needle entry point. (b)
Large gray consolidated mass affecting the majority of the left cranial lung lobe. Fibrous tissue can be seen adherent to the lung surface just cranial and ventral to the
needle entry point. (c) One large dark colored mass affecting the right cranial lung lobe containing the implant site, with a further focal lesion within the left caudal
lung lobe.
Following the implantation procedure, a CT scan was
performed to assess for complications and to evaluate final
sensor positioning. Although numerous TTNB associated
complications have been documented which include infection,
air embolism, lung lobe torsion, and needle tract metastasis,
by far the most common complications are pneumothorax and
hemorrhage (64).
Although pneumothorax rates as high as 54% have been
documented (65, 66), accepted occurrence rates are more likely
to be in the region 17–26%, of which ∼14% will require
percutaneous aspiration or chest tube insertion (57, 60, 67, 68).
In our series of experiments, 4 out of 9 cases (44%) developed a
mild immediate post-implantation pneumothorax, however only
2 required percutaneous needle thoracocentesis. The cases that
received thoracocentesis resulted in lung lobe expansion, with
the sensor remaining within the OPA lesion. In each case the
pneumothorax did not reoccur; this was likely due to the removal
of excess pleural air from around the implant site, allowing
apposition of visceral and parietal pleural surfaces. Measures that
were used to reduce the risk of pneumothorax included the use
of a coaxial needle, to allow the sensor to be placed with a single
pleural puncture, and careful needle path planning.
Although hemorrhage is the second most common TTNB
complication that occurs in ∼4–10% of cases (67, 69), the
development of a haemothorax is <1% (64). Bleeding may be
identified through blood coming up through the bore of the
needle, or as a ground-glass appearance on CT images typically
in the region of the biopsy or along the needle path. Measures
that were used to reduce the risk of hemorrhage included
the avoidance of large pulmonary and cardiovascular vessels.
Placing the needle through the center of the intercostal space
also reduced the risk of damage to intercostal neurovascular
bundles. In our study no cases were identified as having
post-implantation hemorrhage based on CT image evaluation;
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FIGURE 10 | Histological appearance of OPA sensor implantation site. All images are haematoxylin and eosin stained sections. OPA tissue including the implantation
site was obtained during the post-mortem examination. The top image shows the needle tract penetrating through the visceral pleura (right-hand side of image) and
into the OPA tissue. Large numbers of erythrocytes can be seen within the needle tract. Higher magnification images document erythrocytes extending up to 250µm
from the implant site, predominately within stromal tissue.
however, following post-mortem examination and implant site
histopathology erythrocytes were identified within the needle
tract in all cases. This finding is not unexpected as tumor
tissue can have an extensive blood supply. Passage of a large
needle through tumor parenchyma will inevitably damage intra-
tumoural macro and microvessels. This situation is also likely to
occur in human patients undergoing TTNB, but as the needle
tract itself would never be biopsied there is no available data to
support this. Limited amounts of erythrocytes were identified in
OPA tissue away from the needle tract itself. It is possible that the
OPA tissue immediately adjacent to the implant site and needle
tract has reduced compliance compared with normal lung tissue,
and could potentially act as a tamponade, preventing the escape
of erythrocytes into the tumor tissue. The under reporting of
alveolar hemorrhage based on the CT images is likely due to the
appearance of the OPA lesions themselves. All cases had large
OPA lesions involving the visceral pleura that were characterized
as having increased radiopacity, frequently with the presence of
air bronchograms. This CT appearance of typical OPA tumors
would have likely obscured any hemorrhage that occurred within
the needle tract itself.
The large needle size required for sensor implantation
probably contributed to the complication rate encountered in the
model. The needle diameter had to exceed that of the IMPACT
sensor and lead wire. Consequently, an 8G Jamshidi needle was
selected, which is considerably larger than the 18–22G needles
that would be routinely used in human TTNB procedures.
Ongoing development and miniaturization of the sensors will
allow smaller diameter needles to be used. Although smaller
diameter needles may reduce the occurrence of complications,
our current model has shown a comparable complication rate to
that seen in human patients undergoing TTNB.
Although not considered within this article, the primary aim
of developing this novel OPA model was to validate the in vivo
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functionality of the IMPACT O2 and pH sensors within a tumor
microenvironment. In order to achieve this goal, we performed a
series of physiological challenges following sensor implantation.
These challenges included altering blood oxygenation levels
through FIO2 manipulations and varying blood pH levels though
administering inhaled CO2 and altering ventilation rates. The
results of sensor validation experiments will be published in
separate articles and will highlight the ability of the OPA model
to be used to validate novel medical technologies.
CONCLUSION
This paper has described the use of naturally-occurring pre-
clinical OPA cases in the development of a novel in vivo
ovine model for the CT-guided trans-thoracic percutaneous
implantation of sensors into OPA tumors. This is, to the
best of our knowledge, the first description of the use of
naturally-occurring OPA cases as a surgical model. Through the
integration of techniques such as ultrasound, general anesthesia,
CT and surgery into the OPA model, we have demonstrated its
translational potential and effectiveness as a pre-clinical research
tool for human lung cancer. We have also shown our model to be
comparable to TTNB in human patients in terms of procedure
duration, radiation exposure, and complication rate. We believe
this model can be developed further for other pre-clinical uses,
such as the procurement of biopsy specimens, the development of
medical devices for the local delivery of chemotherapeutic agents,
monitoring the tumor microenvironment and in the assessment
of the effectiveness of RT or systemic chemotherapeutic agents.
This model has great potential to not only advance the molecular
understanding of human lung cancer, but to also improve pre-
clinical research and enhance the treatment of human lung
cancer patients.
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